Nevertheless, a validated network meta-analysis to rank ALKIs as first-line treatment in patients with ALK-positive advanced NSCLC with regards to PFS, OS, ORR, and safety concerns is urgently needed. This evidence concerns the gene ALK and non-small cell lung carcinoma.